Remimazolam during cardiopulmonary bypass
Not Applicable
Recruiting
- Conditions
- Cardiocascular surgery
- Registration Number
- JPRN-jRCT1011230015
- Lead Sponsor
- Yoshikawa Yusuke
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Patients who receive cardiovascular surgery under cardiopulmonary bypass with mild hypothermia
Exclusion Criteria
Refusal to participate
Emergent case
Allergy against remimazolam
Acute angle closure glaucoma
Myasthenia gravis
Hepatic failure (Child Pugh equal to or more than 2)
Renal failure (sCre equal to or more than 2 mg/dL)
Obesity (BMI equal to or more than 35 kg/m2)
Deep hypothermic circulatory arrest
Patients who are considered to be inappropriate to participate to the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentration of free remimazolam
- Secondary Outcome Measures
Name Time Method Concentration of total remimazolam, protein binding ratio of remimazolam, concentration of a metabolite of remimazolam (CNS7054), concentration of albumin, blood gas analysis, hemodynamics, BIS value, body temperature, time of blood sampling <br>patients characteristics, surgery type, duration of anesthesia, duration of aortic clamp, duration of cardiopulmonary bypass, amount of fluid, dose of vasoactive agents, dose of anesthetics, amount of blood products, bleeding, urine output